HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Ruchika
University of California San Francisco, United States
Title : Understanding ABC transporters to navigate human diseases


Membrane proteins constitute 30% of genome in organisms and are involved in numerous physiological processes. ABC transporters is a class of membrane proteins which are ubiquitously present in all organisms, bind and hydrolyze ATP to power the solute transport and are associated with several human diseases like multidrug resistance in cancer, macular degeneration, cystic fibrosis, retinitis pigmentosa etc. ABC transporters consists of two transmembrane domains (TMDs), which form the permeation pathway and nucleotide binding domains (NBDs) to bind and hydrolyze ATP and follow alternating access mechanism. Bacterial ABC transporters like binding-protein-independent mutant of maltose transporter, MalG511 from E.coli and FtsEX-PcsB from S. pneumoniae have been characterized biochemically and biophysically to study mechanism and future higher resolution studies. Oral excipients were screened against P-gp using calceinAM fluorescence assay and digoxin flux assay were found to be inert for their effect on P-glycoprotein. beta-Cyclodextrin and light green SF yellowish were found to be inhibitory at high macromolecular range in digoxin flux assay. This information will be helpful in preparing novel generic formulations.  


Ruchika has BSc (H) Biochemistry from University of Delhi and MSc. Biotechnology from Indian Institute of Technology Roorkee, India and received her PhD from Purdue University where she was trained as a Membrane Protein Biologist. Afterwards, she pursued her postdoctoral training at UCSF. She focused on ABC transporters all the way in her scientific training. She is very much passionate in elucidating in mechanistic underpinning of membrane proteins using biochemical, biophysical and structural biology approaches, which could help to rationally design novel pharmacological tools to modulate the function of membrane proteins altered in disease.